ESSA Pharma (EPIX) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research cut shares of ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) from a hold rating to a sell rating in a research report released on Thursday, Zacks.com reports.

According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “

Separately, HC Wainwright restated a buy rating on shares of ESSA Pharma in a research note on Friday, February 15th.

ESSA Pharma stock traded down $0.11 during midday trading on Thursday, reaching $2.32. The stock had a trading volume of 200 shares, compared to its average volume of 4,298. ESSA Pharma has a 12 month low of $1.87 and a 12 month high of $4.69. The stock has a market capitalization of $15.15 million, a P/E ratio of -0.84 and a beta of 2.35. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.54 and a current ratio of 2.44.

ESSA Pharma Company Profile

ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Featured Article: Google Finance

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.